Related Experiment Video
Updated: Mar 15, 2026
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
10.1K
Outcomes and Readmissions After Continuous Flow Left Ventricular Assist Device: Heartmate II Versus Heartware
O N Tuncer1, C Kemaloğlu2, O Erbasan2
1Erzincan Universıty, Mengücek Gazi Training and Research Hospital, Cardiovascular Surgery Department, Erzincan, Turkey.
Transplantation Proceedings
|August 30, 2016
Summary
Donor organ shortage necessitates alternatives like the HeartMate II and HeartWare left ventricular assist devices. While comparable, HeartWare showed better survival, but HeartMate II had more bleeding and infection, while HeartWare had more strokes and thrombosis.
Area of Science:
- Cardiology
- Medical Devices
- Surgical Innovation
Background:
- Donor organ shortage remains a critical issue in heart transplantation, limiting treatment options for end-stage heart disease patients.
- Continuous flow pumps, such as HeartMate II and HeartWare, offer alternative solutions for patients awaiting transplantation.
- These devices have demonstrated clinical success in managing advanced heart failure.
Purpose of the Study:
- To compare the clinical outcomes and complications of HeartMate II and HeartWare left ventricular assist devices (LVADs).
- To evaluate the safety and efficacy of these two continuous flow pumps in patients with end-stage heart disease.
Main Methods:
- A retrospective study of 55 patients who received either HeartMate II or HeartWare LVAD implantation between 2011 and 2014.
- Patients were monitored for complications, including infections, bleeding, organ dysfunction, and thromboembolic events.
- Comparative analysis of preoperative characteristics, intraoperative outcomes, and device-related adverse events.
Main Results:
- The HeartMate II group was significantly older than the HeartWare group; no other significant preoperative differences were noted.
- HeartWare demonstrated a trend towards better 1-year survival, though not statistically significant.
- Higher incidences of gastrointestinal bleeding and driveline infection were observed in the HeartMate II group, whereas the HeartWare group experienced more strokes and pump thrombosis.
Conclusions:
- HeartMate II and HeartWare LVADs are largely comparable in terms of survival, intraoperative parameters, and overall major complication rates.
- Despite similarities, specific complication profiles differ, with HeartMate II associated with bleeding/infection and HeartWare with stroke/thrombosis.
- Both devices represent viable options for managing end-stage heart failure, with patient selection potentially influenced by risk profiles for specific complications.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
582
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
582
01:22Heart Failure VI: Adjunct Therapies
501
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
501
01:30Cardiomyopathy II: Dilated Cardiomyopathy
716
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716
01:21Cardiac Catheterization II: Right Heart Catheterization
1.6K
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
1.6K
01:30Heart Failure V: Medical Management
465
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
465
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K